This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Richard Surtees
Richard Surtees
Associate
London +44 20 7067 2187 rsurtees@cov.com Download V-card

Richard Surtees is an associate in Covington’s corporate department, having joined the firm as a trainee solicitor in 2013.

Mr. Surtees advises both public and private companies on a wide range of matters, including mergers and acquisitions, capital market transactions and employee benefits. Mr. Surtees has particular focus on the design, corporate governance requirements and shareholder communication of share incentive schemes, both in the context of corporation transactions and on an advisory basis.

  • Advised Heptares Therapeutics Limited on employee benefit and UK tax aspects on its sale to Sosei Group, for initial consideration of $180 million and up to an additional $220 million contingent on the success of Heptares’ pipeline and platform.
  • Advised Kesios Therapeutics Limited on its £19.5 million Series A financing by a syndicate of investors including Abingworth, Imperial Innovations and SVLS. Kesios is developing novel therapeutics for the treatment of multiple myeloma and other cancers.
  • Assisted Qualcomm, Inc. on the unwinding of existing employee and executive share option plans in connection with its £1.56 billion recommended cash offer for CSR plc.
  • Assisted Indivior plc (formerly RB Pharmaceuticals) on employee benefit and UK tax aspects relating to its demerger from Reckitt Benckiser and £1 billion listing on the London Main Market.
  • Represented Ergomed plc:
    • on its flotation on the AIM market of the London Stock Exchange, an associated fundraising and its simultaneous acquisition of PrimeVigilance Limited; and
    • executive management on the share scheme arrangements implemented as part of its IPO, and the subsequent grant of long term incentive awards.
  • Advised Consort Medical plc, listed on the London Main Market, in connection with its £230 million acquisition of Aesica Holdco Limited.
  • Assisted a number of venture backed biotech companies on the set up and implementation of employee share plans namely, HMRC qualifying Enterprise Management Incentive plans.
  • Advised Canaccord Genuity Limited as NOMAD and broker to AIM listed EKF Diagnostics Holding plc on its £26 million fundraise by way of an accelerated book build and related acquisitions of U.S.-based Selah Genomics Inc. and Swedish-based DiaSpect Medical AB.
  • Advised Horizon Discovery Group plc on its initial public offering and admission to the AIM market of the London Stock Exchange, raising approximately £40 million before expenses for Horizon and a further £28.6 million for selling shareholders.
  • Advised Lombard Medical, Inc. on its $55 million U.S. initial public offering and the listing of the company’s ordinary shares on the NASDAQ Global Market.

Pro Bono

  • Acted for a spinout pharmaceutical company specializing in the development of anemia diagnostic devices.
  • Advised a UK-registered charity focused on investing in clean and safe water projects globally.

Memberships and Affiliations

  • Share Plan Lawyers Group, Member